KIAA1683, also known as Astrotactin 2 (ASTN2), is a protein that plays a crucial role in neuronal migration and the architectural structuring of the brain. This protein functions by mediating the adhesion between migrating neurons and the glial fibers along which they move, a process fundamental to the proper layering and organization of neurons in the developing brain. ASTN2's activity is vital for the formation of structured neural networks, which are essential for effective neural function and connectivity. In addition to its roles in development, ASTN2 may also be involved in synaptic plasticity and the maintenance of neural circuits in adulthood, suggesting its importance in both brain development and its ongoing function.
The inhibition of KIAA1683/ASTN2 can disrupt normal brain development and function, potentially leading to neurological deficits or disorders. Inhibition could occur through various biological mechanisms, including genetic mutations that result in the loss of function or reduced expression of the ASTN2 gene. Such genetic variations can diminish the production or functional capability of the ASTN2 protein, thereby impairing neuron migration and proper brain layering. Additionally, post-translational modifications such as phosphorylation or ubiquitination might alter the protein's stability, localization, or interaction with other proteins, further inhibiting its function in neuron adhesion and migration. Environmental factors, such as toxins or nutritional deficiencies, could also play a role in inhibiting ASTN2 function indirectly by affecting the cellular environment and the molecular pathways that regulate protein expression and activity. Understanding these inhibition mechanisms is essential for elucidating the pathophysiological basis of related neurological conditions and could be crucial for developing intervention strategies that address these developmental anomalies.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
A PPARα agonist affecting lipid metabolism, which can influence KIAA1683 if involved in lipid-related cellular activities. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
A proteasome inhibitor which can affect protein degradation, offering insight into KIAA1683’s role in this area. | ||||||
VX 809 | 936727-05-8 | sc-474670 | 10 mg | $592.00 | ||
A CFTR corrector affecting chloride channel regulation, potentially affecting KIAA1683's involvement in ion homeostasis. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets RAF kinases and VEGFRs, influencing cell proliferation and angiogenesis, thereby affecting KIAA1683 if involved in these pathways. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A DNA methyltransferase inhibitor affecting gene expression, potentially modifying KIAA1683’s regulatory functions. | ||||||
Mebendazole | 31431-39-7 | sc-204798 sc-204798A | 5 g 25 g | $46.00 $89.00 | 2 | |
Impacts microtubule function and might offer insights into KIAA1683's role in cellular architecture. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
An HMG-CoA reductase inhibitor affecting cholesterol biosynthesis, possibly affecting KIAA1683 if it plays a role in lipid homeostasis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets EGFR and inhibits tyrosine kinase activity, affecting KIAA1683 if it operates within these signaling routes. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Inhibits JAK2, potentially affecting STAT signaling pathways, and consequently the functions KIAA1683 may be involved in. | ||||||